TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Bioline RX Ltd Sponsored ADR ( (BLRX) ) is now available.
On November 24, 2025, BioLineRx Ltd. announced its financial results for the third quarter of 2025 and provided a corporate update. The company highlighted the formation of a joint venture with Hemispherian AS to advance GLIX1, a novel small molecule targeting DNA damage response in glioblastoma and other cancers, with a Phase 1/2a clinical trial expected to start in Q1 2026. Additionally, BioLineRx is progressing with its CheMo4METPANC Phase 2b clinical trial for motixafortide in metastatic pancreatic cancer and has received a Notice of Allowance from the USPTO for a key patent covering GLIX1. Financially, BioLineRx reported $0.4 million in revenue from royalties and maintains a cash runway into the first half of 2027.
The most recent analyst rating on (BLRX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Bioline RX Ltd Sponsored ADR stock, see the BLRX Stock Forecast page.
Spark’s Take on BLRX Stock
According to Spark, TipRanks’ AI Analyst, BLRX is a Neutral.
Bioline RX Ltd’s overall stock score reflects significant revenue growth and promising pipeline developments. However, ongoing financial challenges, including negative net income and high leverage, weigh heavily on the score. The technical indicators suggest a bearish trend, and the valuation highlights the lack of immediate investor returns. The earnings call provides some optimism for future growth, but financial and operational challenges maintain a balanced outlook.
To see Spark’s full report on BLRX stock, click here.
More about Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a development stage biopharmaceutical company focused on creating innovative therapies in the fields of oncology and rare diseases. The company is actively involved in advancing its drug development pipeline, particularly targeting high-need cancer indications such as glioblastoma, and is also engaged in the development of treatments for pancreatic cancer and sickle cell disease.
Average Trading Volume: 35,278
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.14M
For detailed information about BLRX stock, go to TipRanks’ Stock Analysis page.